1. Home
  2. NCPL vs INTS Comparison

NCPL vs INTS Comparison

Compare NCPL & INTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Netcapital Inc.

NCPL

Netcapital Inc.

HOLD

Current Price

$1.44

Market Cap

17.0M

Sector

Finance

ML Signal

HOLD

Logo Intensity Therapeutics Inc.

INTS

Intensity Therapeutics Inc.

SELL

Current Price

$3.50

Market Cap

13.7M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
NCPL
INTS
Founded
1984
2012
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
17.0M
13.7M
IPO Year
2022
2021

Fundamental Metrics

Financial Performance
Metric
NCPL
INTS
Price
$1.44
$3.50
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
★ $19.33
AVG Volume (30 Days)
★ 10.1M
16.7K
Earning Date
12-14-2026
11-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ N/A
EPS
★ N/A
N/A
Revenue
★ $869,460.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$0.21
$0.22
52 Week High
$2.66
$8.06

Technical Indicators

Market Signals
Indicator
NCPL
INTS
Relative Strength Index (RSI) 51.79 46.63
Support Level $0.43 $3.10
Resistance Level $1.87 $4.04
Average True Range (ATR) 0.47 0.23
MACD -0.05 0.04
Stochastic Oscillator 31.87 69.09

Price Performance

Historical Comparison
NCPL
INTS

About NCPL Netcapital Inc.

Netcapital Inc is a financial technology company. The company facilitates the growth of private companies by providing fundraising services and other consulting services. The company's online private investment platform connects entrepreneurs and investors, enabling companies to raise capital digitally. The Company operates in a single operating segment, which is the provision of fintech services.

About INTS Intensity Therapeutics Inc.

Intensity Therapeutics Inc is a late-stage clinical biotechnology company passionately committed to applying scientific leadership in the field of localized cancer reduction to anti-cancer immune activation. Its new approach involves the direct injection into tumors of a product created from DfuseRxSM discovery platform. Its platform creates patented anti-cancer product candidates comprising active anti-cancer agents and amphiphilic molecules. Its product candidate, INT230-6 comprised of three components: cisplatin, a anti-cancer cytotoxic agent, vinblastine sulfate, also a anti-cancer cytotoxic agent, and an amphiphilic molecule which enables the two cytotoxic agents to disperse through a tumor and diffuse into cancer cells following a direct intratumoral injection.

Share on Social Networks: